Atrial tachyarrhythmia recurred in 39 patients treated with Boston Scientific’s Farapulse PFA device, while 53 people had recurrence in the Medtronic cryoablation group.

Pulsed field ablation (PFA) was noninferior to cryoballoon ablation for the incidence of a first recurrence of atrial ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Nearly 10 Product Candidates Under Development are Expected to be Commercialized in the Next Three YearsHONG KONG, Apr 1, 2025 - (JCN Newswire) - Cryofocus Medtech (Shanghai) Co., Ltd. ('Cryofocus Med ...

In 2024, Cryofocus Medtech’s revenue has maintained a strong growth trend within the interventional cryotherapy industry. The total revenue of Cryofocus Medtech increased by 30.7% YoY to RMB53.5 ...

Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...

Q4 2024 Earnings Call Transcript March 27, 2025 IceCure Medical Ltd misses on earnings expectations. Reported EPS is $-0.08 ...

Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 ...

Somashekharayya Hiremath said As an inventor, I have contributed to multiple projects and patents, shaping energy-based ...

IceCure Medical Ltd. ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor ...

"Given the novelty of our product and the importance of breast cancer in public health, the FDA has included many stakeholders in the discussion of the De Novo marketing clearance for ProSense ...

CAESAREA, Israel, March 20, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...